SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)

被引：0

作者：

Tedeschi, A. ^{[1
]}

Trotman, J. ^{[2
,3
]}

Zinzani, P. ^{[4
]}

Cavallo, F. ^{[5
]}

Marasca, R. ^{[6
]}

Liberati, A. ^{[7
]}

Linton, K. ^{[8
]}

Mckay, P. ^{[9
]}

Hu, B. ^{[10
]}

Coleman, M. ^{[11
]}

Ardeshna, K. ^{[12
,13
]}

Bijou, F. ^{[14
]}

Marcus, R. ^{[15
]}

Portell, C. ^{[16
]}

Thieblemont, C. ^{[17
]}

Bachy, E. ^{[18
]}

Costello, R. ^{[19
]}

Iyengar, S. ^{[20
]}

Mocikova, H. ^{[21
]}

Co, M. ^{[22
,23
]}

Li, X. ^{[22
,23
]}

Zhou, W. ^{[22
,23
]}

Cappellini, M. ^{[22
,23
]}

Tankersley, C. ^{[22
,23
]}

Huang, J. ^{[22
,23
]}

Opat, S. ^{[24
,25
]}

机构：

[1] ASST Grande Osped Metropolitano Niguarda, Milan, Italy

[2] Concord Repatriat Gen Hosp, Concord, Australia

[3] Univ Sydney, Sydney, NSW, Australia

[4] Univ Bologna, Inst Hematol Serognoli, Bologna, Italy

[5] Azienda Osped Citto Salute & Sci Torino, Turin, Italy

[6] AOU Policlin Modena, Modena, Italy

[7] Azienda Osped Santa Maria Terni, Terni, Italy

[8] The Christie, Manchester, Lancs, England

[9] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[10] Levine Canc Inst Atrium Hlth, Charlotte, NC USA

[11] Clin Res Alliance, New Hyde Pk, NY USA

[12] Univ Coll London NHS Fdn Trust, Dept Haematol, London, England

[13] UCLH NIHR Biomed Res Ctr, London, England

[14] Inst Bergonie, Bordeaux, France

[15] Sarah Cannon Res Inst UK, London, England

[16] Univ Virginia Hlth Syst, Charlottesville, VA USA

[17] Paris Univ Diderot, Hop St Louis, APHP, Hematooncol, Paris, France

[18] Ctr Hosp Lyon Sud, Pierre Benite, France

[19] Hop Conception APHM, Marseille, France

[20] Royal Marsden Hosp, London, England

[21] Fak Nemocnice Kralovske Vinohrady, Prague, Czech Republic

[22] BeiGene BeifingCo Ltd, Beijing, Peoples R China

[23] BeiGene USA Inc, Cambridge, MA USA

[24] Monash Hlth, Clayton, Vic, Australia

[25] Monash Univ, Clin Haematol Unit, Clayton, Vic, Australia

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

C044

引用

页码：35 / 35

页数：1

共 50 条

[31] Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
Denlinger, Nathan M.
Epperla, Narendranath
William, Basem M.
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 615 - 624
[32] The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
Horwitz, Steven M.
Soto, Jasminder
Youssoufian, Hagop
Lloyd, Deborah
Le, Ngocdiep T.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study
Armand, Philippe
Ansell, Stephen M.
Lesokhin, Alexander M.
Halwani, Ahmad
Millenson, Michael M.
Schuster, Stephen J.
Timmerman, John
Borrello, Ivan
Gutierrez, Martin
Scott, Emma C.
Cattry, Deepika
Chapuy, Bjoern
Ligon, Azra H.
Rodig, Scott J.
Zhu, Lili
Grosso, Joseph F.
Kim, Su Young
Shipp, Margaret A.
BLOOD, 2014, 124 (21)
[34] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Song, Yuqin
Zhou, Keshu
Yang, Shenmiao
Hu, Jianda
Zou, Dehui
Gao, Sujun
Pan, Ling
Wang, Tingyu
Yang, Haiyan
Zhang, Huilai
Zhou, Daobin
Ji, Jie
Xu, Wei
Feng, Ru
Jin, Jie
Lv, Fangfang
Huang, Haiwen
Fan, Xiaosi
Xu, Sheng
Zhu, Jun
INVESTIGATIONAL NEW DRUGS, 2023, 41 (04) : 606 - 616
[35] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Yuqin Song
Keshu Zhou
Shenmiao Yang
Jianda Hu
Dehui Zou
Sujun Gao
Ling Pan
Tingyu Wang
Haiyan Yang
Huilai Zhang
Daobin Zhou
Jie Ji
Wei Xu
Ru Feng
Jie Jin
Fangfang Lv
Haiwen Huang
Xiaosi Fan
Sheng Xu
Jun Zhu
Investigational New Drugs, 2023, 41 : 606 - 616
[36] Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma
Satoshi Yamasaki
Dai Chihara
Isao Yoshida
Kyuhei Kohda
Masashi Sawa
Hiroatsu Ago
Kazuto Togitani
Yuju Ohno
Junji Tanaka
Takahiro Fukuda
Yoshiko Atsuta
Junji Suzumiya
Ritsuro Suzuki
Annals of Hematology, 2019, 98 : 1521 - 1523
[37] Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma
Yamasaki, Satoshi
Chihara, Dai
Yoshida, Isao
Kohda, Kyuhei
Sawa, Masashi
Ago, Hiroatsu
Togitani, Kazuto
Ohno, Yuju
Tanaka, Junji
Fukuda, Takahiro
Atsuta, Yoshiko
Suzumiya, Junji
Suzuki, Ritsuro
ANNALS OF HEMATOLOGY, 2019, 98 (06) : 1521 - 1523
[38] Impact of Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Marginal Zone Lymphoma
Yamasaki, Satoshi
Chihara, Dai
Yoshida, Isao
Kohda, Kyuhei
Sawa, Masashi
Ago, Hiroatsu
Togitani, Kazuto
Ohno, Yuju
Tanaka, Junji
Fukuda, Takahiro
Atsuta, Yoshiko
Suzumiya, Junji
Suzuki, Ritsuro
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[39] Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Martin, Peter
Armas, Armando
Gopal, Ajay K.
Gyan, Emmanuel
Wagner-Johnston, Nina D.
Walewski, Jan
Abella, Steve
Ye, Wei
Philip, Betsy
Sorenson, Bess
de Vos, Sven
BLOOD, 2015, 126 (23)
[40] Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)
Martin, P.
Armas, A.
Gopal, A.
Gyan, E.
Wagner-Johnston, N.
Walewski, J.
Abella, S.
Ye, W.
Philip, B.
Sorenson, B.
de Vos, S.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 100 - 100

← 1 2 3 4 5 →